{"id":"NCT01421134","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","officialTitle":"A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2011-08-22","resultsPosted":"2015-10-09","lastUpdate":"2016-07-15"},"enrollment":211,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder With Mixed Features"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":["Latuda"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lurasidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.","primaryOutcome":{"measure":"Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"Lurasidone","deltaMin":-20.5,"sd":0.95},{"arm":"Placebo","deltaMin":-13,"sd":1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":43,"countries":["United States","Russia","Serbia","Ukraine","United Kingdom"]},"refs":{"pmids":["30086213","29943445","26908089"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":109},"commonTop":["Insomnia","Anxiety","Headache","Nausea","Dizziness"]}}